Low-Grade Glioma Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

What industry-specific factors are fueling the growth of the low-grade glioma market?
The growing incidence of brain tumors is expected to drive the expansion of the low-grade glioma market in the near future. A brain tumor refers to an abnormal cell growth within the brain or nearby regions, which can be benign or malignant. The rise in brain tumor cases is linked to factors such as increased radiation exposure, environmental pollutants, genetic factors, and aging. Low-grade glioma treatments for brain tumors include advanced diagnostic techniques and targeted therapies like surgery, radiation, and chemotherapy, which help slow tumor progression, preserve neurological functions, and improve patient outcomes. Early detection and personalized treatments are critical for managing other brain tumors with similar growth patterns. For instance, in October 2023, the Central Brain Tumor Registry of the United States (CBTRUS), a nonprofit organization, revealed that in 2022, the global incidence of primary malignant brain tumors was about 3.5 per 100,000 people, with higher rates in high-income countries (4.9 per 100,000) compared to low- and middle-income countries (2.4 per 100,000). Thus, the rising incidence of brain tumors is fueling the growth of the low-grade glioma market.

Get Your Low-Grade Glioma Market Report Here:
https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

What Is the projected market size and growth rate for the low-grade glioma market?
The low-grade glioma market has seen strong growth, increasing from $1.39 billion in 2024 to $1.48 billion in 2025 at a CAGR of 6.1%. Growth has been driven by increased awareness of brain tumors, greater oncology research funding, an increase in orphan drug designations, the expansion of telemedicine, and better healthcare access.

The low-grade glioma market is projected to witness considerable growth, reaching $1.86 billion by 2029 at a CAGR of 5.9%. The driving factors for this growth include an aging population, rising healthcare expenditures, an increasing prevalence of brain tumors, greater government support for cancer research, and a rise in the incidence of high-grade gliomas. Key trends shaping this market include advancements in imaging technology, innovations in radiation therapies, development of chemotherapy protocols, expansion of clinical trials, and the increasing integration of immunotherapy.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

What new trends are reshaping the low-grade glioma market and its opportunities?
In the low-grade glioma (LGG) market, companies are integrating combination therapies and targeted therapies, such as genetic alteration drugs, to treat children with LGG. Genetic alteration drugs target specific mutations to block pathways that promote cancer cell growth. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotech company, launched Tovorafenib (Ojemda) after receiving accelerated FDA approval. Tovorafenib is a targeted therapy for children with unresectable or recurrent LGG with BRAF gene alterations. This once-weekly oral treatment provides a new option for pediatric LGG patients with limited previous treatment options.

What major market segments define the scope and growth of the low-grade glioma market?
The low-grade glioma market covered in this report is segmented -

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib
2) By Treatment: Surgery, Chemotherapy, Radiation
3) By Route Of Administration: Topical, Oral
4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21215

Which region dominates the low-grade glioma market?
North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the low-grade glioma industry growth?
Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

What Is Covered In The Low-Grade Glioma Global Market Report?

•Market Size Forecast: Examine the low-grade glioma market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the low-grade glioma market for a structured understanding.
•Key Players Overview: Analyze major players in the low-grade glioma market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the low-grade glioma market.
•Segment Contributions: Evaluate how different segments drive overall growth in the low-grade glioma market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the low-grade glioma market.
•Industry Challenges: Identify potential risks and obstacles affecting the low-grade glioma market.
•Competitive Landscape: Review strategic developments in the low-grade glioma market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.